Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Trial Profile

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Tucatinib (Primary) ; Capecitabine; Trastuzumab
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HER2CLIMB
  • Sponsors Cascadian Therapeutics
  • Most Recent Events

    • 11 Sep 2017 According to a Cascadian Therapeutics media release, the study is currently enrolling patients in the United States, Canada, Western Europe and Australia.
    • 08 Aug 2017 According to a Cascadian Therapeutics media release, the first patients has been randomized in Western Europe and Australia in this trial.
    • 11 Jul 2017 According to Cascadian Therapeutics media release, postive results from this study could serve this as a single registrational trial for submission of a Marketing Authorization Application (MAA) to the EMA and potential marketing approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top